CXCL1 and Alzheimer disease: The interaction between astrocytic CXCL1 and neuronal CXCR2 receptors exacerbates the synaptotoxic effects of Aβ and is expected to serve as a novel target for the treatment of AD (Perez-Nievas et al., 2021).